Peptides Similar to Teduglutide
Compare Teduglutide with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •BPC-157: Low to moderate - Both are peptides with gastrointestinal healing properties, but through entirely different mechanisms and for different indications
- •GLP-1: Moderate - Both are proglucagon-derived peptide analogs that act through related but distinct receptor pathways
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Teduglutide (current) | - | - |
| BPC-157 | Low to moderate - Both are peptides with gastrointestinal healing properties, but through entirely different mechanisms and for different indications | BPC-157 is a pentadecapeptide with broad cytoprotective and tissue-healing properties. Teduglutide is a GLP-2 receptor agonist that specifically promotes intestinal mucosal growth. Teduglutide is FDA-approved while BPC-157 remains a research compound. |
| GLP-1 | Moderate - Both are proglucagon-derived peptide analogs that act through related but distinct receptor pathways | GLP-1 analogs target the GLP-1 receptor to regulate glucose metabolism and appetite. Teduglutide targets the GLP-2 receptor to promote intestinal growth. Despite structural similarity and co-secretion from L-cells, the receptor systems mediate completely different physiological effects. |
BPC-157Low to moderate - Both are peptides with gastrointestinal healing properties, but through entirely different mechanisms and for different indications
Differences
BPC-157 is a pentadecapeptide with broad cytoprotective and tissue-healing properties. Teduglutide is a GLP-2 receptor agonist that specifically promotes intestinal mucosal growth. Teduglutide is FDA-approved while BPC-157 remains a research compound.
Advantages
FDA-approved with extensive clinical trial data, defined mechanism through GLP-2 receptor, proven efficacy in reducing parenteral nutrition dependence, established dosing and monitoring protocols
Disadvantages
Requires subcutaneous injection, neoplasia monitoring with regular colonoscopies, expensive (listed price over $30,000/month), limited to SBS indication
GLP-1Moderate - Both are proglucagon-derived peptide analogs that act through related but distinct receptor pathways
Differences
GLP-1 analogs target the GLP-1 receptor to regulate glucose metabolism and appetite. Teduglutide targets the GLP-2 receptor to promote intestinal growth. Despite structural similarity and co-secretion from L-cells, the receptor systems mediate completely different physiological effects.
Advantages
Unique intestinotrophic activity not replicated by GLP-1 analogs, addresses intestinal failure rather than metabolic disease
Disadvantages
Much smaller patient population than GLP-1 analog indications, narrower therapeutic application, requires specialist prescribing and monitoring
Compounds Related to Teduglutide#
Teduglutide is the first and currently the only approved GLP-2 receptor agonist. However, several next-generation GLP-2 analogs are in clinical development that aim to improve upon teduglutide's pharmacokinetic profile.
Next-Generation GLP-2 Analogs#
Two GLP-2 analogs in clinical development offer potentially longer dosing intervals than teduglutide's once-daily requirement:
Apraglutide (VectivBio/Ironwood): A long-acting GLP-2 analog designed for once-weekly subcutaneous administration. Phase 3 trials in SBS-IF are ongoing. The extended half-life could significantly reduce injection burden for patients already managing complex parenteral nutrition regimens.
Glepaglutide (Zealand Pharma): Another long-acting GLP-2 analog with weekly dosing potential. Phase 3 results in SBS-IF have shown efficacy in reducing parenteral support, with approval under regulatory review.
| Parameter | Teduglutide | Apraglutide | Glepaglutide |
|---|---|---|---|
| Dosing frequency | Once daily | Once weekly | Once weekly |
| Approval status | FDA/EMA approved | Phase 3 | Phase 3/filed |
| Administration | SC injection | SC injection | SC injection |
| Half-life | 2-3 hours | ~30 hours | ~50 hours |
| Indication | SBS-IF | SBS-IF | SBS-IF |
BPC-157#
BPC-157 is a pentadecapeptide with broad gastrointestinal cytoprotective properties. While both peptides have GI-relevant mechanisms, their approaches are fundamentally different. Teduglutide acts through a defined receptor (GLP-2R) with a specific trophic mechanism, while BPC-157 affects multiple pathways including angiogenesis, nitric oxide signaling, and growth factor modulation. Teduglutide has extensive clinical trial data and regulatory approval, while BPC-157 remains primarily a research compound.
GLP-1 Analogs#
GLP-1 and GLP-2 are both derived from proglucagon and co-secreted from intestinal L-cells, but they activate distinct receptor systems with different physiological effects. GLP-1 analogs (semaglutide, liraglutide, tirzepatide) regulate glucose homeostasis, appetite, and body weight. Teduglutide exclusively promotes intestinal growth and has no metabolic effects. The two peptide families serve entirely different patient populations and therapeutic goals.
Comparison Context#
Teduglutide belongs to the Healing category of research peptides. Comparing Teduglutide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Teduglutide in mechanism, indication, or therapeutic category:
Teduglutide vs BPC-157#
Similarity: Low to moderate - Both are peptides with gastrointestinal healing properties, but through entirely different mechanisms and for different indications
Key Differences: BPC-157 is a pentadecapeptide with broad cytoprotective and tissue-healing properties. Teduglutide is a GLP-2 receptor agonist that specifically promotes intestinal mucosal growth. Teduglutide is FDA-approved while BPC-157 remains a research compound.
Advantages of BPC-157: FDA-approved with extensive clinical trial data, defined mechanism through GLP-2 receptor, proven efficacy in reducing parenteral nutrition dependence, established dosing and monitoring protocols
Disadvantages of BPC-157: Requires subcutaneous injection, neoplasia monitoring with regular colonoscopies, expensive (listed price over $30,000/month), limited to SBS indication
Researchers choosing between Teduglutide and BPC-157 should consider the development stage, available evidence, and specific research objectives when making their selection.
Teduglutide vs GLP-1#
Similarity: Moderate - Both are proglucagon-derived peptide analogs that act through related but distinct receptor pathways
Key Differences: GLP-1 analogs target the GLP-1 receptor to regulate glucose metabolism and appetite. Teduglutide targets the GLP-2 receptor to promote intestinal growth. Despite structural similarity and co-secretion from L-cells, the receptor systems mediate completely different physiological effects.
Advantages of GLP-1: Unique intestinotrophic activity not replicated by GLP-1 analogs, addresses intestinal failure rather than metabolic disease
Disadvantages of GLP-1: Much smaller patient population than GLP-1 analog indications, narrower therapeutic application, requires specialist prescribing and monitoring
Researchers choosing between Teduglutide and GLP-1 should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Teduglutide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer